Repositioning Drugs for Rare Diseases Based on Biological Features and Computational Approaches
Open Access
- 16 September 2022
- journal article
- research article
- Published by MDPI AG in Healthcare
- Vol. 10 (9) , 1784
Abstract
Rare diseases are a group of uncommon diseases in the world population. To date, about 7000 rare diseases have been documented. However, most of them do not have a known treatment. As a result of the relatively low demand for their treatments caused by their scarce prevalence, the pharmaceutical industry has not sufficiently encouraged the research to develop drugs to treat them. This work aims to analyse potential drug-repositioning strategies for this kind of disease. Drug repositioning seeks to find new uses for existing drugs. In this context, it seeks to discover if rare diseases could be treated with medicines previously indicated to heal other diseases. Our approaches tackle the problem by employing computational methods that calculate similarities between rare and non-rare diseases, considering biological features such as genes, proteins, and symptoms. Drug candidates for repositioning will be checked against clinical trials found in the scientific literature. In this study, 13 different rare diseases have been selected for which potential drugs could be repositioned. By verifying these drugs in the scientific literature, successful cases were found for 75% of the rare diseases studied. The genetic associations and phenotypical features of the rare diseases were examined. In addition, the verified drugs were classified according to the anatomical therapeutic chemical (ATC) code to highlight the types with a higher predisposition to be repositioned. These promising results open the door for further research in this field of study.Keywords
Funding Information
- Spanish Ministerio de Ciencia e Innovación (PID2021-122659OB-I00, FPI PRE2019-090912, RTI2018-094576-A-I00, IND2019/TIC-17159)
- Formación de Personal Investigador (PID2021-122659OB-I00, FPI PRE2019-090912, RTI2018-094576-A-I00, IND2019/TIC-17159)
- Spanish Ministerio de Ciencia, Innovación y Universidades (PID2021-122659OB-I00, FPI PRE2019-090912, RTI2018-094576-A-I00, IND2019/TIC-17159)
- Comunidad de Madrid (PID2021-122659OB-I00, FPI PRE2019-090912, RTI2018-094576-A-I00, IND2019/TIC-17159)
This publication has 71 references indexed in Scilit:
- Vincristine exacerbates asymptomatic Charcot–Marie–Tooth disease with a novel EGR2 mutationneurogenetics, 2012
- Drug repositioning for orphan diseasesBriefings in Bioinformatics, 2011
- Dorsolateral Midbrain MRI Abnormalities and Ocular Motor Deficits Following Cytarabine-Based Chemotherapy for Acute Myelogenous LeukemiaJournal of Neuro-Ophthalmology, 2011
- Francis CollinsNature Reviews Drug Discovery, 2010
- Opsoclonus-Myoclonus Syndrome in Patients With Locked-in Syndrome: A Therapeutic Porthole With GabapentinMayo Clinic Proceedings, 2010
- Pediatric Mastocytosis: Routine Anesthetic Management for a Complex DiseaseAnesthesia & Analgesia, 2008
- Rare essentials drugs for rare diseases as essential medicines2006
- Clinical Relevance of Atrial Fibrillation/Flutter, Stroke, Pacemaker Implant, and Heart Failure in Emery-Dreifuss Muscular DystrophyStroke, 2003
- Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicityThe Journal of Pediatrics, 1997
- Alcoholism in hereditary hemochromatosis revisited: Prevalence and clinical consequences among homozygous siblingsHepatology, 1996